Executive Board
The Executive Board has been established to assist the Chief Executive in leading The Institute of Cancer Research to achieve its strategic aims and objectives within the approved strategies and budgets and is responsible for formulating strategies, plans and budgets for approval by the Board of Trustees.
Professor Kristian Helin
Chief Executive and President
Carol Ford
Chief People Officer
Professor Kevin Harrington
Head of Division – Radiotherapy and Imaging
Professor Clare Isacke
Dean of Academic & Research Affairs
Paul Norris
Chief Financial Officer
Professor Jonathon Pines
Head of Division – Cancer Biology
Dr Barbara Pittam
Chief Research and Academic Officer
Dr Olivia Rossanese
Head of Division and Director – Cancer Therapeutics
Latest ICR News
Thousands of blood cancer patients could benefit from new drug combination
Thousands of patients with a common type of blood cancer could benefit from a new drug combination, while others could see their disease kept at bay for longer.
Silencing gene may combat formation of radiation-induced scar tissue, a new study reveals
A new study suggests that silencing CXCL12, a gene involved in tissue scarring and repair, could help reduce the formation of scar tissue that can caused by radiotherapy. Ultimately, the researchers hope this approach could improve treatment outcomes for breast cancer patients undergoing radiotherapy and reconstructive surgery.
_kevin-harrington-embed.jpg?sfvrsn=cb25ea76_1 "t-vec-infected-melanoma-cells-(green)_kevin-harrington-embed")
ASCO 2025: One-time cell therapy offers long-term survival hope for patients with advanced melanoma
A one-time immunotherapy treatment using a patient’s own immune cells has shown long-lasting benefit for people with advanced melanoma, a serious form of skin cancer, according to new five-year follow-up data from a pivotal clinical trial.
ASCO 2025: Next-generation breast cancer drug targets tumours before they have a chance to grow
A powerful new drug for advanced breast cancer can be used to treat emerging tumours, months before they have a chance to grow, helping to keep patients well for longer and delaying the need for later-line therapies including chemotherapy.
Results of a global study, funded by AstraZeneca and co-led by researchers at The Institute of Cancer Research, London, The Royal Marsden NHS Foundation Trust and Institut Curie, Paris, were presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 1 June 2025.